CD274 and cancer: In other words, strategies of immune normalization therapy instead of enhancement of the immune system or a therapeutic direct attack of the cancer cells, has renormalized T‐cell physiology to perform their normal attack of cancer cells through the B7‐H1/PD‐1 pathway, bringing many new oncology “checkpoint blockade” drugs to the market (Zappasodi et al.